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Abstract 
Age reprogramming represents a novel method for generating patient-specific tissues for transplantation. It bypasses 
the de-differentiation/redifferentiation cycle that is characteristic of the induced pluripotent stem (iPS) and nuclear 
transfer-embryonic stem (NT-ES) cell technologies that drive current interest in regenerative medicine. Despite the 
obvious potential of iPS and NT-ES cell-based therapies, there are several problems that must be overcome before 
these therapies are safe and routine. As an alternative, age reprogramming aims to rejuvenate the specialized func-
tions of an old cell without de-differentiation; age reprogramming does not require developmental reprogramming 
through an embryonic stage, unlike the iPS and NT-ES cell-based therapies. Tests of age reprogramming have largely 
focused on one aspect, the epigenome. Epigenetic rejuvenation has been achieved in vitro in the absence of de-
differentiation using iPS cell reprogramming factors. Studies on the dynamics of epigenetic age (eAge) reprogram-
ming have demonstrated that the separation of eAge from developmental reprogramming can be explained largely 
by their different kinetics. Age reprogramming has also been achieved in vivo and shown to increase lifespan in a 
premature ageing mouse model. We conclude that age and developmental reprogramming can be disentangled and 
regulated independently in vitro and in vivo.
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Background
Animal cloning experiments using somatic cell nuclear 
transfer (SCNT) revealed that ageing is reversible. SCNT 
was initially described in amphibians [1, 2] and later in 
mammals [3]. These influential experiments showed that 
nuclear reprogramming of somatic cells was a process by 
which adult differentiated cells reacquired developmental 
and ageing potential (Box  1). The result was a newborn 
clone, which was genetically identical to the somatic cell 
transferred into the recipient oocyte, a clone that now 
possessed the potential of a normal lifespan even when 
the somatic cell was derived from an old donor [4, 5]. 
Thus, measurable age-associated changes found in old 
cells can be reversed by SCNT. More recently, the semi-
nal studies of Yamanaka and colleagues have shown that 
“reprogramming factors”, Oct4, Sox2, Klf4 and c-Myc, can 
reprogram somatic cells into induced pluripotent stem 
(iPS) cells even from an elderly 82-year-old donor [6, 7]. 
Importantly, senescent fibroblasts from elderly donors 
can be de-differentiated into iPS cells by introduction of 
reprogramming factors and then redifferentiated back to 
fibroblasts that have lost the senescent phenotype and 
acquired the characteristics of young fibroblasts [8]. Put-
ting it short, induction of iPS cells can, like NT-ES cells, 
reset the ageing clock.
Both techniques can reverse molecular hallmarks 
of ageing [9]. For example, telomere attrition can be 
reversed by induction of iPS cells whereupon telomerase 
lengthens the telomeres [10]. Telomeres are also extended 
in nuclei of reconstructed embryos [11] although the 
mechanism(s) involved is likely to be more complicated, 
using both telomerase and telomere sister chromatid 
exchange [12]. iPS cells also have reduced DNA damage 
[13] and enhanced mitochondrial function [14]. Cells dif-
ferentiated from iPS cells lose expression of markers of 
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senescence and acquire gene expression profiles of young 
cells [8]. Invariably, the assays used above to demonstrate 
reversal of hallmarks of ageing rely upon de-differenti-
ated embryonic cells or cells derived from them. From 
these data, it would seem that rejuvenation requires pas-
sage through an embryonic stage. Notably, embryonic 
cells and their differentiated derivatives are the substrate 
for regenerative therapies although their use is associated 
with several well-documented disadvantages [15]. One 
of the most serious being the development of teratomas 
when reprogramming factors are expressed in  vivo [16, 
17]. To overcome these drawbacks, a new approach has 
been put forward.
Age reprogramming and epigenetic rejuvenation
On the face of it, nuclear reprogramming observed dur-
ing SCNT and iPS cell production appears seamless—
“developmental reprogramming” to the embryonic, 
pluripotent, state is concomitant with “age reprogram-
ming” that resets the age of the donor nucleus (Box 1). 
This represents a barrier because in order to rejuvenate 
old cells without de-differentiation it is necessary for 
developmental reprogramming to be disentangled from 
age reprogramming [18, 19]. Put another way: Can 
senescent cells be rejuvenated without going through 
an embryonic stage? Thus framed an experimental 
approach was immediately suggested that could test 
whether developmental and age reprogramming are 
separable [19]. iPS cell reprogramming factors would 
be introduced into senescent cells already character-
ized in terms of age-related markers. During the tra-
jectory from senescent cell to iPS cell, a search would 
be made for a stage where the marker(s) were reduced 
or lost, indicating rejuvenation, while the “partially 
reprogrammed” cells would still possess their special-
ized phenotype, i.e. the cells should not exhibit signs of 
de-differentiation (see Figure 2A in [19]). Such partially 
reprogrammed cells will have rejuvenated an aspect of 
ageing and thereby provide evidence that developmen-
tal and age reprogramming are indeed separable. In the 
first experimental test, senescent human diploid fibro-
blasts (HDFs) were used along with a single cell iPS cell 
technique to measure the dynamics of an essential epi-
genetic modifier, HP1β, in senescent cells before and 
after they had started along the path to become iPS 
cells [20]. The choice of the epigenome as a measure 
of rejuvenation was on the basis that epigenetic drift is 
a hallmark of ageing [9, 21]. Care was taken to ensure 
there was no de-differentiation by maintaining cells in 
fibroblast medium rather than switching to stem cell 
medium that is necessary for generation of iPS cells. 
The result was that HP1β mobility was rejuvenated on 
day 9 post-introduction of the reprogramming factors, 
albeit rejuvenation was transient (Fig.  1a). Neverthe-
less, “epigenetic rejuvenation” (Box 1) of HP1β mobility 
confirmed that an aspect of age reprogramming could 
be rejuvenated without concomitant developmental 
reprogramming.
Box 1 Terminology of reprogramming
Nuclear reprogramming is the process by which a differentiated cell reacquires developmental and ageing potential.
Developmental reprogramming is the process by which a differentiated cell reacquires developmental potential.
Age reprogramming is the process by which a differentiated cell reacquires ageing potential.
Epigenetic rejuvenation represents one aspect of age reprogramming and is the process by which an aged epigenotype is reprogrammed to a young 
epigenotype.
(See figure on next page.)
Fig. 1 (e)Age reprogramming using iPS reprogramming factors. a Schematic depiction of the experiment by Manukyan and Singh [20]. 
Fluorescence recovery after photo-bleaching (FRAP) analysis showed that the mobility of the epigenetic modifier, HP1β, in senescent HDFs (blue) 
transduced with OSKML reprogramming factors reached levels found in young HDFs (red) on day 9 after transduction (highlighted with the yellow 
surround). Epigenetic rejuvenation of HP1β mobility is transient and returns to that found in senescent cells on day 12. b Schematic depiction of 
the in silico analysis by Olova et al. [26]. Between days 3 and 7 post-transduction of HDFs (eAge ~ 65 years) with OSKM reprogramming factors, 
eAge (purple line) declines at a steady rate with a gradient (purple dotted line) of 3.8 years per day and falls to zero by day 20. Analysis of the 
expression of three fibroblast-specific gene clusters, F1, F2 and F3 (given in grey), showed that two (F2 and F3) declined immediately and then 
plateaued between days 7 and 15. The F1 cluster remained stable over the first 15 days. A red dotted line passes through day 10, when there 
has been a substantial decrease in eAge that continues to fall, while the expression levels of F1, F2 and F3 remain on a plateau. After day 15, the 
expression of all three clusters declined with the extinguishing of the F1 cluster at day 35. The increase in expression of a cluster of pluripotency 
genes (green) showed that they reach steady-state levels only after eAge had reached zero. The genes in the early pluripotency gene cluster and 
fibroblast-specific gene clusters F1, F2 and F3 are listed in Table 1 of Olova et al. [26]. c Schematic showing that kinetics of eAge and developmental 
reprogramming are different [26]. eAge reprogramming has fallen to zero by day 20. Fibroblast gene expression is extinguished on day 35 and 
marks loss of fibroblast identity, whereupon an iPS cell molecular identity is established. The red dotted line corresponds to that which is described 
in b 
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The transient epigenetic rejuvenation of HP1β pro-
vides evidence that age-related epigenetic changes 
can be reversed without de-differentiation. Of the 
age-related changes that have been described, the 
most well known is DNA methylation and, in particu-
lar, the recently discovered “epigenetic clock” that can 
measure eAge [21]. It is to the epigenetic clock and its 
associated eAge we now turn as recent work indicates 
that eAge provides a robust measure for the degree 
of epigenetic rejuvenation that takes place during age 
reprogramming.
eAge reprogramming
The relationship of DNA methylation with ageing is long 
and well documented [22, 23]. It is now on a firm statis-
tical foundation through the development of an “epige-
netic clock” based on the level of cytosine methylation at 
353 CpG sites in the human genome [21]. The epigenetic 
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clock can be used to predict the eAge of multiple tissues 
and has a strikingly accurate correlation with chronologi-
cal age (r = 0.96) and with a median error of 3.6 years [21, 
24]. Its accuracy is greater than other biological markers 
such as telomere length [25], and all indications are that 
eAge may be a measure of biological age. In this context, 
the foundational study of eAge found that the eAge of ES 
cells and iPS cells is zero [21]. This confirmed that eAge 
had been reprogrammed—eAge of iPS cells was consid-
erably less than the cells from which they were derived. 
However, the question of whether reprogramming of 
eAge is separable from the developmental reprogram-
ming resulting in iPS cells remained open. An answer 
was provided recently using the rationale that had fur-
nished evidence for epigenetic rejuvenation of HP1β 
mobility [20]. Olova et  al. [26] undertook an in silico 
analysis of a previously published 49-day iPS reprogram-
ming time course on HDFs [27] which revealed that 
eAge reprogramming is indeed separable from devel-
opmental reprogramming. They observed a decrease in 
eAge after reprogramming factors were introduced into 
HDFs (eAge ~ 65 years) that began between days 3 and 7 
post-introduction. Thereafter, a steady decrease in eAge 
was measured at 3.8 years per day, reaching zero by day 
20 (Fig.  1b). Notably, the decline in eAge began well in 
advance of the earliest wave of pluripotency gene expres-
sion. Fibroblast-specific expression showed a more 
complex pattern where two of three clusters of fibro-
blast-specific genes showed an immediate decline that 
plateaued from day 7 until day 15, by which time there 
had been a significant drop in eAge. It was on day 35 
that fibroblast-specific gene expression was finally extin-
guished and marked the loss of fibroblast identity. By that 
time, eAge had been zero for 15 days. It would seem that 
age reprogramming as measured by eAge is separable 
from developmental reprogramming as measured by loss 
of somatic identity (Fig. 1c).
The decrease in eAge of 3.8 years/day is striking in its 
regularity. The predictable decrease in eAge may provide 
a mechanism for choosing a preferred eAge by manipu-
lating the timing, duration and levels of expression of iPS 
reprogramming factors.
Age reprogramming in vivo
The transient epigenetic rejuvenation of HP1β mobility 
was a consequence of a single exposure to reprogram-
ming factors (Fig.  1a). Recently, an important advance 
was made where reprogramming factors were expressed 
in cells in a cyclic manner [28]. This regime resulted in 
“partially reprogrammed” cells that exhibited measur-
able attributes of rejuvenation both in  vitro and, more 
importantly, in  vivo (Fig.  2). Initial in  vitro studies 
used short-term expression (2 or 4  days) of the OSKM 
reprogramming factors in fibroblasts from LAKI progeria 
mice harbouring a mutation in the Lamin A gene (Lmna). 
LAKI mice exhibit a premature ageing phenotype [29]. 
Short-term expression of OSKM resulted in epigenetic 
rejuvenation of two heterochromatin-specific markers, 
H3K9me3 and H4K20me3 (Fig. 2; [28]). Reversal of three 
other hallmarks of ageing was also observed, namely: (1) 
recovery of mitochondrial function determined by levels 
of reactive oxygen species, (2) decreased DNA damage 
as measured by 53BP1 and γH2AX and, (3), reduced cel-
lular senescence measured by metalloprotease MMP13, 
Il-6 and β-galactosidase expression (Fig.  2). There was 
also reversal of age-related stress response measured by 
the p53 tumour suppressor pathway. Similar results were 
observed with late passage wild-type murine and human 
fibroblasts indicating that the efficaciousness of short-
term expression was not restricted to age reprogramming 
of cells from progeria mice. Two key insights came when 
fibroblasts from LAKI progeria mice were analyzed after 
OSKM expression was terminated. First, it was shown 
that the age-associated phenotypes return but, strik-
ingly, they could be reversed again if OSKM expression 
was reintroduced: cyclic expression of OSKM maintained 
the reversal of age-associated phenotypes. Second, epi-
genetic changes are the likely driver of ageing, at least 
in  vitro, because administration of the histone lysine 
methyl-transferase inhibitor chaetocin eliminated the 
effect of cyclic expression in LAKI fibroblasts. The cycli-
cal regime for OSKM expression was then used in vivo, 
with expression for 2 days and no expression for 5 days. 
This cycle could be repeated as often as required.
Cyclic expression of OSKM in LAKI mice had a dra-
matic effect. Not only were age-associated features 
reversed but there was also a significant increase in both 
median and maximal life span [26] (Fig. 2). In physiologi-
cally aged wild-type mice, cyclic expression enhanced the 
regenerative capacity of β cells of the pancreas and satel-
lite cells of the muscle after chemical injury (Fig. 2). There 
was no increase in formation of teratomas or mortality 
in vivo. “Partial reprogramming” did not lead to the loss 
of differentiation markers and expression of pluripotency 
markers such as Nanog, indicating that age reprogram-
ming in vivo can be achieved in the absence of develop-
mental reprogramming.
Conclusions and perspectives
Nuclear reprogramming via SCNT and iPS technologies 
is currently understood as a seamless process by which 
a specialized cell reacquires developmental and ageing 
potential [30, 31] (Box  1). This view could require revi-
sion to accommodate evidence that rather than being 
an indivisible process, nuclear reprogramming is multi-
layered and its constituent components may be separable 
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experimentally (Fig.  3). There is considerable evidence 
to support the bifurcation of nuclear reprogramming 
into age and developmental reprogramming as initially 
hypothesized [19]. In particular, the dynamics of age and 
developmental reprogramming show that their kinet-
ics are very different; age reprogramming is complete, as 
measured by eAge, well before the loss of somatic identity 
that results from developmental reprogramming (Fig. 1b, 
c). Moreover, molecular hallmarks of ageing can be age-
reprogrammed (rejuvenated without de-differentiation; 
Box  1), as observed by epigenetic rejuvenation [20, 26, 
28], a decrease in DNA damage and cellular senescence 
[28], and reduced mitochondrial dysfunction [28] (Figs. 1 
and 2). Future studies will determine whether other 
hallmarks can be so rejuvenated thereby placing age 
reprogramming on a footing independent to and experi-
mentally separable from developmental reprogramming. 
It will also be of great interest to investigate whether 
hallmarks of ageing can be age-reprogrammed indepen-
dently of each other.
Age reprogramming has several advantages over cur-
rent regenerative therapies [18] including direct repro-
gramming where trans-differentiation of fibroblasts into 
another cell type, without passage through an embry-
onic stage, has been shown not to reprogram hallmarks 
of ageing [32]. In short, age reprogramming enables the 
generation of rejuvenated cells for regenerative therapies, 
without having to go through a de/redifferentiation cycle 
[18]. Nevertheless, there is some way to go before age 
reprogramming can be seen as a viable alternative to the 
iPS and NT-ES cell therapies currently being developed. 
Work on “interrupted reprogramming” has shown prom-
ise in cell replacement therapy in mice, although the reju-
venated status of the engrafted cells was not determined 
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Fig. 2 Age reprogramming in vivo. Schematic depiction of the experiment by Ocampo et al. [28]. Top row: Short-term or cyclic (2 days “on” and 
5 days “off”) expression of OSKM reprogramming factors in fibroblasts from LAKI progeria mice (blue) lead to age reprogramming of epigenetic 
rejuvenation, DNA damage, senescence, mitochondrial dysfunction and stress response. The first four characteristics are known hallmarks of ageing 
[9]. Age-reprogrammed fibroblast from the LAKI progeria mouse is given in red. Similar results were obtained with old wild-type murine and human 
fibroblasts. Middle row: Cyclic expression of OSKM reprogramming factors in LAKI progeria mouse leads to age reprogramming of DNA damage, 
senescence, stress response and epigenetic rejuvenation. The mice also exhibit enhanced regeneration of satellite cells in the muscle after chemical 
injury. They also have increased median and maximal lifespan. Bottom row: Cyclic expression of OSKM reprogramming factors in 12-month-old 
wild-type mice promotes regeneration of β cells in the pancreas and satellite cells of the muscle after chemical injury. Other parameters were not 
tested and are given as a question mark. An upward facing arrow depicts an increase in a particular characteristic after cyclic OSKM expression and 
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[33]. A study that addressed this issue using mesenchymal 
stromal cells (MSCs) concluded that interrupted repro-
gramming does not rejuvenate MSCs, albeit the indicated 
caveats for this study included, inter alia, uncontrolled 
heterogeneous expression of reprogramming factors 
from episomal vectors [34]. Age reprogramming in vivo 
will, most probably, be driven by development of efficient 
methods for delivering reprogramming factors to sites of 
injury or disease. Small molecules that can substitute for 
the classical reprogramming gene products [35] will be in 
the vanguard of in vivo studies due to the ease of crossing 
cell membranes. Tailoring the chemical nature, timing 
and quantity of reprogramming factors could also have 
the added advantage of avoiding the possibility of devel-
oping teratomas that can arise from unfettered expres-
sion of classical iPS reprogramming factors in  vivo [16, 
17]. All these are goals for the future. At the pace we are 
now advancing it should not be long before there will be 
signs that they can be achieved.
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